Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002871 (
anemia
)
52,094
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fanconi
anemia
(FA) is a rare multigenic chromosomal instability syndrome that predisposes patients to life-threatening bone marrow failure, congenital malformations, and cancer. Functional loss of interstrand cross-link (ICL) DNA repair system is held responsible, though the mechanism is not yet fully understood. The clinical and molecular findings of 20 distinct FA cases, ages ranging from perinatal stage to 32 years, are presented here. Pathogenic variants in
FANCA
were found responsible in 75%,
FANCC, FANCE, FANCJ
/
BRIP1
, FANCL
in 5%, and
FANCD1
/
BRCA2
and
FANCN
/
PALB2
in 2.5% of the subjects. Altogether, 25 different variants in 7 different FA genes, including 10 novel mutations in
FANCA, FANCN
/
PALB2, FANCE,
and
FANCJ
/
BRIP1
,
were disclosed. Two compound heterozygous germline cases were mosaic for one allele, revealing that the incidence of reverse mutations may not be uncommon in FA. Another case with de novo
FANCD1/BRCA2
and paternally inherited
FANCN/PALB2
pathogenic alleles at first glance suggested a digenic inheritance, because the presence of a second pathogenic variant in the unexamined regions of
FANCD1/BRCA2
and
FANCN/PALB2
were exluded by sequencing and deletion/duplication analysis. A better understanding of the complexity of the FA genotype may provide further access to undiscovered ICL components and apparently dispensable cellular pathways where FA proteins may play important roles.
...
PMID:Clinical and Molecular Characterization of Fanconi Anemia Patients in Turkey. 3322 12
<< Previous
1
2
3
4
5
6